Bio-Rad Laboratories (BIO) Stock Price, News & Analysis

Company Overview

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Key Stats

• Today's Range: $334.51 to $338.35
• 50-Day Range: $313.15 to $374.28
• 52-Week Range: $262.12 to $387.99
• Volume: 27,661 shs
• Average Volume: 240,533 shs
• Market Capitalization: $9.38 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $394.20
• Consensus Rating: Moderate Buy

Bio-Rad Laboratories Stock Analysis - MarketRank™

Bio-Rad Laboratories scored higher than 89% of companies evaluated by MarketBeat, and ranked 131st out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Bio-Rad Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Bio-Rad Laboratories has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 11.95%

Earnings Growth

Earnings for Bio-Rad Laboratories are expected to grow by 11.95% in the coming year, from $10.29 to $11.52 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bio-Rad Laboratories is -12.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bio-Rad Laboratories is -12.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Bio-Rad Laboratories has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.55% of the float of Bio-Rad Laboratories has been sold short.

Short Interest Ratio / Days to Cover

Bio-Rad Laboratories has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bio-Rad Laboratories has recently decreased by 6.83%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bio-Rad Laboratories does not currently pay a dividend.

Dividend Growth

Bio-Rad Laboratories does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.54

Percentage of Shares Shorted

2.55% of the float of Bio-Rad Laboratories has been sold short.

Short Interest Ratio / Days to Cover

Bio-Rad Laboratories has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bio-Rad Laboratories has recently decreased by 6.83%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.44

News Sentiment

Bio-Rad Laboratories has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Bio-Rad Laboratories this week, compared to 6 articles on an average week.

Search Interest

Only 7 people have searched for BIO on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.

MarketBeat Follows

6 people have added Bio-Rad Laboratories to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bio-Rad Laboratories insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.06% of the stock of Bio-Rad Laboratories is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

65.24% of the stock of Bio-Rad Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BIO Stock Analysis - Frequently Asked Questions

How have BIO shares performed this year?

Bio-Rad Laboratories' stock was trading at $322.89 at the beginning of 2024. Since then, BIO shares have increased by 4.5% and is now trading at $337.28.
View the best growth stocks for 2024 here.

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO) released its earnings results on Wednesday, October, 30th. The medical research company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.85. Bio-Rad Laboratories's revenue for the quarter was up 2.8% on a year-over-year basis.
Read the conference call transcript.

Does Bio-Rad Laboratories have any subsidiaries?

Bio-Rad Laboratories subsidiaries include Dropworks Inc., Celsee, Raindance Technologies Limited, GnuBIO Inc., Bio-Rad AbD Serotec GmbH, Propel Labs - Cell Sorting System Division, QuantaLife, and others.

Who are Bio-Rad Laboratories' major shareholders?

Bio-Rad Laboratories' top institutional shareholders include Van ECK Associates Corp (4.57%), Veritas Asset Management LLP (3.81%), State Street Corp (2.27%) and UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (1.58%). Insiders that own company stock include Andrew J Last, Michael Crowley, Timothy S Ernst, Dara Wright, James Barry and Ajit Ramalingam.
View institutional ownership trends.

How do I buy shares of Bio-Rad Laboratories?

Shares of BIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Bio-Rad Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bio-Rad Laboratories investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

• Last Earnings: 10/30/2024
• Today: 12/18/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Analytical instruments
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NYSE:BIO
• CUSIP: 09057220
• CIK: 12208
• Web: www.bio-rad.com
• Phone: (510) 724-7000
• Fax: 510-741-5817
• Employees: 8,030
• Year Founded: 1952

Price Target and Rating

• Average Stock Price Target: $394.20
• High Stock Price Target: $481.00
• Low Stock Price Target: $315.00
• Potential Upside/Downside: +16.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($27.33)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 32.78
• P/E Growth: N/A
• Net Income: $-637,320,000.00
• Net Margins: -30.18%
• Pretax Margin: -38.96%
• Return on Equity: 3.74%
• Return on Assets: 2.65%

Debt

• Debt-to-Equity Ratio: 0.16
• Current Ratio: 6.14
• Quick Ratio: 4.52

Sales & Book Value

• Annual Sales: $2.58 billion
• Price / Sales: 3.66
• Cash Flow: $11.96 per share
• Price / Cash Flow: 28.21
• Book Value: $306.51 per share
• Price / Book: 1.10

Miscellaneous

• Outstanding Shares: 27,997,000
• Free Float: 23,221,000
• Market Cap: $9.44 billion
• Optionable: Optionable
• Beta: 0.90